“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

05 July 2019
Pharma

Visiongain has launched a new pharma report Global Influenza Vaccines Market Outlook 2019-2029: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.

Growth is mainly driven by the ageing population and the increasing prevalence of health problems associated with age. This will drive the demand from both the developing and the developed world for influenza vaccines. The emerging markets will benefit from improved healthcare systems and in turn they will add to the demand of the influenza vaccines owing to their high birth rates. Furthermore, research and development will lead to continuous innovation within the vaccines industry. Advancements will be made in the delivery and target technology used in the influenza vaccines.

The lead analyst of the report commented "The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market. There is an increasing focus to identify the research gaps and unmet needs of the influenza vaccines market. This includes vaccine technology that provides wider coverage and easier access and administration of the influenza vaccines. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create newer influenza vaccine technology that is not already on the market. This prevents stagnation within the market and will help drive the growth of the influenza vaccines market."

Leading companies featured in the report include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Sinovac Biotech and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biologics Market Report 2020-2030

Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.

06 August 2020

Read

Visiongain Publishes Biochips Market Report 2020-2030

Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.

05 August 2020

Read

Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030

With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.

03 August 2020

Read

Visiongain Publishes Advanced Wound Care Market Report 2020-2030

Traditional wound care such as gauze and compression therapies are less effective than active wound care products. Active wound dressings create an environment more suitable for healing.

03 August 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever